Recently, Hangzhou winonco Medical Technology Co., Ltd. successfully held at Guangzhou Fuda Cancer Hospital the kick-off meeting for the clinical trial project “Treatment of Malignant Pulmonary Nodules” using the broad-spectrum synergistic pulse ablation device (Wknife) developed and produced by Hangzhou winonco Medical Technology Co., Ltd. This clinical trial project is led by President Niu Lizhi of Guangzhou Fuda Cancer Hospital as the principal investigator. The holding of this kick-off meeting marks that the “Wknife” product developed by our company, following the treatment of liver cancer and benign prostatic hyperplasia (BPH), has also embarked on a new journey in the treatment of pulmonary diseases.

This clinical trial is designed to prospectively evaluate the efficacy, safety and feasibility of the broad-spectrum synergistic pulse ablation device in the treatment of malignant pulmonary nodules, bringing good news to more patients. The study has been approved by the Medical Ethics Committee of Guangzhou Fuda Cancer Hospital, the institution has agreed to establish the project, and it has been filed with the Zhejiang Medical Products Administration (filing number: Zhejiang Medical Device Clinical Trial Filing No. 20230891).

This malignant pulmonary nodule clinical trial is now openly recruiting participants from the public——

#ZHAO MU#

Recruitment

If you, or someone around you, is a patient who meets the following criteria and is able to receive treatment, return visits and examinations in accordance with the doctor’s requirements, you may sign up to participate:

1. Age: 18–70 years old, no gender restriction;

1. Malignant pulmonary nodule confirmed by cytology or histopathology, or oligometastatic pulmonary nodules with ≤3 tumors, a maximum diameter ≤2 cm and a stable primary lesion, with no uncontrolled metastasis at other sites;

3. Unable to undergo surgery or the patient refuses surgical treatment;

4. Maximum nodule diameter ≤2 cm;

5. ECOG performance status ≤2;

6. The patient understands the trial process and voluntarily signs the informed consent form.

(The above are important inclusion criteria; whether a participant ultimately passes screening and is enrolled in the study is determined by the study physician.)

You may contact Guangzhou Fuda Cancer Hospital through the following channels. The hospital will follow up on your subsequent treatment and follow-up visits throughout the whole process, providing you with convenience in accessing care.

Hangzhou winonco Medical Technology Co., Ltd. is a high-tech company that drives innovative medical technology R&D oriented by clinical needs, and focuses on developing minimally invasive tumor treatment solutions.

The winonco R&D team is a pioneer and trailblazer in the theory and practice of irreversible electroporation for tumors. Since 2000, when it was the first in the world to propose the new concept of treating tumors with irreversible electroporation, it has successively proposed and developed three generations of irreversible electroporation technology, consistently leading the global upgrading and replacement of irreversible electroporation medical products.

You are welcome to follow us and witness together how minimally invasive tumor treatment solutions are forged.